SPARCL1 and prostate carcinoma: However, the expression level of SPARCL1 was strongly decreased in most human cancers such as colorectal carcinoma, gastric cancer, and prostate carcinoma, suggesting the potential role to reduce cell proliferation and inhibit DNA synthesis [8–10].